Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CLPP | Q16740 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961887 | 0.84 | CLPP (0.39) | NPC1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1959835 | 0.84 | CLPP (0.38) | NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1959748 | 0.82 | CLPP (0.37) | CLPPCYP11B1CYP11B2ALDH1A1DAO | |
| SCHEMBL1962303 | 0.82 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2CLPPMAOB | |
| SCHEMBL1960359 | 0.81 | NPC1 (0.35) | NPC1CLPPALDH1A1HPGDKDM4E | |
| SCHEMBL1962577 | 0.79 | MAPK13 (0.39) | CYP1A2CYP2D6CLPPCYP11B1CYP11B2 | |
| SCHEMBL1959641 | 0.75 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2CLPPMEN1 | |
| SCHEMBL2345294 | 0.75 | CXCR2 (0.39) | CLPPMAPK1ALDH1A1HPGDKDM4E | |
| SCHEMBL1961441 | 0.74 | PTGES (0.40) | NPC1RAB9ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1958963 | 0.73 | OPRK1 (0.37) | NPC1RAB9ASMN1; SMN2CLPPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | claimed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | claimed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | claimed |
| EP-2332938-B1 | Viral inhibitors | LEUVEN K U RES & DEV (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2332938-A1 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-06-15 | — | — | EP | disclosed |
| US-7737162-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | NPC1 607/4885RAB9A 1537/4885SMN1; SMN2 3179/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | NPC1 562/4885RAB9A 2520/4885SMN1; SMN2 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.